home / stock / ntgn / ntgn quote
Last: | $3.07 |
---|---|
Change Percent: | 8.1% |
Open: | $2.96 |
Close: | $3.07 |
High: | $3.09 |
Low: | $2.915 |
Volume: | 3,604,103 |
Last Trade Date Time: | 05/05/2020 04:47:24 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.07 | $2.96 | $3.07 | $3.09 | $2.915 | 3,604,103 | 05-05-2020 |
$2.84 | $2.79 | $2.84 | $2.92 | $2.74 | 211,934 | 05-04-2020 |
$2.77 | $2.84 | $2.77 | $2.88 | $2.64 | 338,081 | 05-01-2020 |
$2.89 | $2.99 | $2.89 | $2.99 | $2.8163 | 149,480 | 04-30-2020 |
$3.01 | $2.88 | $3.01 | $3.03 | $2.8 | 551,833 | 04-29-2020 |
$2.8 | $2.97 | $2.8 | $2.97 | $2.71 | 206,351 | 04-28-2020 |
$2.92 | $2.91 | $2.92 | $3 | $2.86 | 335,501 | 04-27-2020 |
$2.91 | $3 | $2.91 | $3.0676 | $2.8 | 238,892 | 04-24-2020 |
$2.97 | $3.28 | $2.97 | $3.35 | $2.93 | 1,006,660 | 04-23-2020 |
$3.09 | $3.17 | $3.09 | $3.28 | $2.64 | 2,282,369 | 04-22-2020 |
$2.43 | $2.55 | $2.43 | $2.62 | $2.3001 | 269,711 | 04-21-2020 |
$2.48 | $2.35 | $2.48 | $2.74 | $2.35 | 789,965 | 04-20-2020 |
$2.4 | $2.3 | $2.4 | $2.43 | $2.225 | 453,716 | 04-17-2020 |
$2.14 | $2.22 | $2.14 | $2.22 | $2.125 | 39,695 | 04-16-2020 |
$2.24 | $2.29 | $2.24 | $2.36 | $2.11 | 105,030 | 04-15-2020 |
$2.33 | $2.35 | $2.33 | $2.4023 | $2.24 | 177,138 | 04-14-2020 |
$2.26 | $2.46 | $2.26 | $2.51 | $2.25 | 170,240 | 04-13-2020 |
$2.46 | $2.45 | $2.46 | $2.55 | $2.37 | 331,357 | 04-10-2020 |
$2.46 | $2.45 | $2.46 | $2.55 | $2.37 | 330,688 | 04-09-2020 |
$2.37 | $2.34 | $2.37 | $2.41 | $2.3 | 125,674 | 04-08-2020 |
News, Short Squeeze, Breakout and More Instantly...
Neon Therapeutics Inc. Company Name:
NTGN Stock Symbol:
NASDAQ Market:
Neon Therapeutics Inc. Website:
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority (DHA) for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01. Neon...
BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020 COVID-19 vaccine program BNT162 set to enter the clinic in April 2020 Ended 2019 with cash equivalents of $583 million ( €520 millio...
NEW YORK, NY / ACCESSWIRE / February 13, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Forescout Technologies, Inc. (NASDAQ: FSCT )...